Open Access

Prevalence of human cytomegalovirus, polyomaviruses, and oncogenic viruses in glioblastoma among Japanese subjects

  • Yumiko Hashida1,
  • Ayuko Taniguchi2,
  • Toshio Yawata3,
  • Sena Hosokawa1,
  • Masanao Murakami1,
  • Makoto Hiroi4,
  • Tetsuya Ueba3 and
  • Masanori Daibata1Email author
Infectious Agents and Cancer201510:3

https://doi.org/10.1186/1750-9378-10-3

Received: 29 October 2014

Accepted: 21 January 2015

Published: 27 January 2015

Abstract

Background

The association between human cytomegalovirus (HCMV) and glioblastoma multiforme (GBM) is becoming a new concept. However, information on the geographic variability of HCMV prevalence in GBM remains scarce. Moreover, the potential roles of various viruses, such as polyomaviruses and oncogenic viruses, in gliomagenesis remain unclear. Our aim was to investigate the prevalence of HCMV in GBM among Japanese patients. Furthermore, this was the first study that evaluated infection with four new human polyomaviruses in GBMs. This study also provided the first data on the detection of human papillomavirus (HPV) in GBM in the Eastern world.

Methods

We measured the number of various viral genomes in GBM samples from 39 Japanese patients using real-time quantitative PCR. The tested viruses included HCMV, Merkel cell polyomavirus, human polyomavirus (HPyV) 6, HPyV7, HPyV9, Epstein–Barr virus, human herpesvirus 8, and HPV. Our quantitative PCR analysis led to the detection of eight copies of the HCMV DNA mixed with DNA extracted from 104 HCMV-negative cells. The presence of HCMV and HPV genomes was also assessed by nested PCR. Immunohistochemical study was also carried out to detect HPV-derived protein in GBM tissues.

Results

The viral DNAs were not detectable, with the exception of HPV, which was present in eight out of 39 (21%) GBMs. All HPV-positive cases harbored high-risk-type HPV (HPV16 and HPV18). Moreover, the HPV major capsid protein was detected in GBM tumor cells.

Conclusions

In contrast with previous reports from Caucasian patients, we did not obtain direct evidence in support of the association between HCMV and GBM. However, high-risk-type HPV infection may play a potential etiological role in gliomagenesis in a subset of patients. These findings should prompt further worldwide epidemiological studies aimed at defining the pathogenicity of virus-associated GBM.

Keywords

Oncogenic viruses HCMV HPV Polyomaviruses Glioblastoma Epidemiology

Background

A significant portion of human cancer cases worldwide, an estimated 15%–20%, may be attributed to viral infection [1]. Several studies have indicated an exciting connection between human cytomegalovirus (HCMV) infection and glioblastoma multiforme (GBM), which is the most malignant primary brain tumor of human adults. In these studies, HCMV gene sequences were detected in >90%–95% of cases of GBM, and lower levels of HCMV expression in tumors were associated with longer survival of patients with GBM [28]. Furthermore, recent studies demonstrated a survival benefit in patients with GBM who received standard therapy for GBM in combination with antiviral valganciclovir treatment [9, 10], although this remains to be confirmed by additional studies. Thus, the role of HCMV in the pathogenicity of GBM is attracting increasing interest.

In contrast with these findings, several conflicting reports indicated a lack of association between HCMV and GBM [1113]. A more recent study used next-generation sequencing to show that HCMV sequences are absent in high-grade gliomas [14]. Thus, the association between HCMV and GBM reported by some but not all studies highlights the need for additional worldwide surveys. In fact, to date, all investigations of links between HCMV and GBM have stemmed from American and European populations, and the prevalence of HCMV in GBMs in other regions of the world, such as Asia, has not been clarified. Recently, Yamashita et al. [15] collected GBM samples from hospitals located in the Nagoya area of Japan and tested them for the presence of the HCMV genome; however, none of their cases had detectable HCMV DNA sequences. To determine the frequency at which HCMV is present in Asian populations, we further investigated the prevalence of HCMV and viral load in GBMs from Japanese subjects, using highly sensitive quantitative PCR.

If HCMV infection is an important risk factor for the development of most cases of GBM, it would be worth exploring whether other infectious pathogens coexist with HCMV in these tumors, possibly as cofactors of pathogenesis. For example, several studies suggested that some polyomaviruses, such as the simian virus 40 (SV40) and JC virus (JCV), are associated with GBM [16, 17]. In this context, we explored for the first time the existence of newly discovered human polyomaviruses, including Merkel cell polyomavirus (MCPyV), human polyomavirus 6 (HPyV6), HPyV7, and HPyV9, in GBM samples. MCPyV is the first oncogenic polyomavirus and was originally found in Merkel cell carcinoma [18]; subsequent studies showed that MCPyV DNA was present in other malignancies, such as cervical cancer and lung cancer [19, 20]. In addition, we defined the prevalence of three human oncogenic viruses in GBMs: Epstein–Barr virus (EBV); human herpesvirus 8 (HHV8); and human papillomavirus (HPV). Our study provided the first data on the detection of high-risk-type HPVs in GBMs in the Eastern world.

Results

Quantitative PCR for HCMV in GBMs

To detect HCMV DNA, we employed quantitative PCR targeting two different HCMV regions using the primers and probes for major immediate early (IE) and glycoprotein B (gB) genes [21, 22]. The primers and probes were verified using DNA from a plasmid containing the HCMV IE or gB genes, DNA extracted from the HCMV AD169 strain (Advanced Biotechnologies, Columbia, MD, USA), and DNA from the AD169 strain admixed with cellular DNA. A standard curve for HCMV was generated using serial dilutions of the genome of the AD169 strain. Our quantitative PCR analysis detected at least 1.5 HCMV copies per PCR reaction (i.e., 0.0008 copies per cell) from the AD169 strain DNA admixed with 200 ng of cellular DNA extracted from HCMV-negative HEK293 cells. The number of cells in each sample was assessed by comparing the amounts of RNaseP product. The estimated number of cells per PCR reaction in the GBM samples varied from 5 to 7315 (median, 301; mean, 1028) cells. For positive controls of HCMV detection, three formalin-fixed paraffin-embedded (FFPE) samples were obtained from patients with HCMV pancreatitis (denoted as HCMV-P1), HCMV enteritis (HCMV-P2), and HCMV pneumonia (HCMV-P3), respectively. The number of HCMV copies in these positive controls was 415, 472, and 3852 copies per reaction, or 24.1, 3.82, and 399.55 copies per cell, respectively. In clear contrast, the HCMV IE and gB genes were not detectable in any of the 39 GBMs. All samples were tested at least in triplicate. The results are summarized in Table 1.
Table 1

Results of real-time quantitative PCR to detect various viruses in the 39 patients with GBM and in positive control samples

   

Viral DNA copy number*

Case no.

Age

Sex

HCMV

MCPyV

HPyV6

HPyV7

HPyV9

EBV

HHV8

HPV

Cell number

gB

IE

PCR**

Type 16

Type 18

PCR***

1

60

F

0

0

ND

0

0

0

0

0

0

0

0

ND

32

2

58

F

0

0

ND

0

0

0

0

0

0

0

0

ND

676

3

51

M

0

0

ND

0

0

0

0

0

0

0

0

type 16

417

4

74

F

0

0

ND

0

0

0

0

0

0

0

0

ND

1280

5

72

M

0

0

ND

0

0

0

0

0

0

0.13

0

type 16

21

6

68

F

0

0

ND

0

0

0

0

0

0

0

0

ND

135

7

49

M

0

0

ND

0

0

0

0

0

0

0

0

ND

770

8

71

M

0

0

ND

0

0

0

0

0

0

0

0

type 16

118

9

60

M

0

0

ND

0

0

0

0

0

0

0

0

ND

370

10

42

M

0

0

ND

0

0

0

0

0

0

0

0

ND

34

11

42

M

0

0

ND

0

0

0

0

0

0

0

0

ND

221

12

82

F

0

0

ND

0

0

0

0

0

0

0

0

ND

1236

13

40

M

0

0

ND

0

0

0

0

0

0

0

0

ND

48

14

77

M

0

0

ND

0

0

0

0

0

0

0

0

ND

301

15

62

F

0

0

ND

0

0

0

0

0

0

0

0

ND

454

16

75

M

0

0

ND

0

0

0

0

0

0

0

0

ND

138

17

73

M

0

0

ND

0

0

0

0

0

0

0

0

ND

26

18

43

F

0

0

ND

0

0

0

0

0

0

0

0

ND

157

19

50

F

0

0

ND

0

0

0

0

0

0

0

0

ND

133

20

46

M

0

0

ND

0

0

0

0

0

0

0

0

ND

5

21

82

M

0

0

ND

0

0

0

0

0

0

0

0

ND

114

22

4

F

0

0

ND

0

0

0

0

0

0

0

0

ND

954

23

46

M

0

0

ND

0

0

0

0

0

0

0

0

ND

533

24

70

F

0

0

ND

0

0

0

0

0

0

0

0

ND

590

25

65

F

0

0

ND

0

0

0

0

0

0

0

0

ND

33

26

59

F

0

0

ND

0

0

0

0

0

0

0

0

type 16

400

27

72

M

0

0

ND

0

0

0

0

0

0

0

0

ND

147

28

77

M

0

0

ND

0

0

0

0

0

0

0

0

ND

272

29

65

F

0

0

ND

0

0

0

0

0

0

0

0.05

type 18

50

30

72

M

0

0

ND

0

0

0

0

0

0

0

0

ND

214

31

77

M

0

0

ND

0

0

0

0

0

0

0

0

type 16

388

32

51

F

0

0

ND

0

0

0

0

0

0

0

0

ND

2637

33

77

F

0

0

ND

0

0

0

0

0

0

0

0

ND

5269

34

80

M

0

0

ND

0

0

0

0

0

0

0

0

ND

7022

35

81

M

0

0

ND

0

0

0

0

0

0

0

0

ND

3510

36

63

F

0

0

ND

0

0

0

0

0

0

0

0

ND

3205

37

70

M

0

0

ND

0

0

0

0

0

0

0

0

type 16

7315

38

70

M

0

0

ND

0

0

0

0

0

0

0

0

ND

705

39

88

F

0

0

ND

0

0

0

0

0

0

0

0.18

type 18

170

HCMV-P1a

  

827.37

2.01

          

17

HCMV-P2

  

671.98

270.96

          

123

HCMV-P3

  

3955.12

3748.20

          

10

MCPyV-P1

     

25879.50

        

188

MCPyV-P2

     

28.95

        

275

HPyV6-P1

      

107.60

       

92

HPyV6-P2

      

2.12

       

10

HPyV6-P3

      

0.20

       

254

HPyV7-P1

       

0.12

      

26

HPyV7-P2

       

0.45

      

10

HPyV7-P3

       

0.45

      

672

EBV-P1

         

61315.24

    

2316

EBV-P2

         

47466.54

    

2520

HHV8-P1

          

49621.12

   

1624

HPV16-P1

           

3.66

  

32

HPV16-P2

           

235.94

  

228

HPV16-P3

           

491.46

  

348

HPV16-P4

           

46.06

  

522

HPV18-P1

            

0.11

 

496

HPV18-P2

            

82.98

 

572

HPV18-P3

            

4.58

 

1191

HPV18-P4

            

0.04

 

10

*Viral DNA copy number is shown as per reaction.

**Results of nested PCR are also shown.

***Results of nested PCR and the HPV type are shown.

aPositive controls are as follows: HCMV-P1, HCMV+ pancreatitis (FFPE); HCMV-P2, HCMV+ enteritis (FFPE); HCMV-P3, HCMV+ pneumonia; MCPyV-P1, MCPyV+ Merkel cell carcinoma (FFPE); MCPyV-P2, MCPyV+ cutaneous squamous cell carcinoma (FFPE); HPyV6-P1, HPyV6+ basal cell carcinoma (FFPE); HPyV6-P2, HPyV6+ melanoma (FFPE); HPyV6-P3, HPyV6+ cutaneous squamous cell carcinoma (FFPE); HPyV7-P1, HPyV7+ basal cell carcinoma (FFPE); HPyV7-P2, HPyV7+ melanoma (FFPE); HPyV7-P3, HPyV7+ cutaneous squamous cell carcinoma (FFPE); EBV-P1 and -P2, EBV+ lymphoblastoid cells (cell lines); HHV8-P1, HHV8+ KS-1 (cell line); HPV16-P1 and -P2, HPV16+ cervical cancer (FFPE); HPV16-P3 and –P4, HPV16+ oropharyngeal cancer (FFPE); HPV18-P1 and –P2, HPV18+ cervical cancer (FFPE); HPV18-P3 and –P4, HPV18+ oropharyngeal cancer (FFPE).

F: female; M: male; ND: not detected.

We also analyzed the GBM samples for the existence of HCMV DNA by nested PCR with primer sets targeting the HCMV gB gene, as previously reported [2, 23]. Likewise, HCMV DNA was not detectable in any of our GBM samples (Table 1).

Detection of human polyomaviruses and oncogenic viruses

Next, we tested the GBM samples for the presence of four human polyomaviruses (MCPyV, HPyV6, HPyV7, and HPyV9) and three oncogenic viruses (EBV, HHV8, and HPV). These viral DNAs were not detected, with the exception of HPV, which was detected in three out of 39 GBMs by real-time quantitative PCR targeting HPV16 and HPV18 sequences (Table 1). One patient was infected with HPV16 and two patients with HPV18, and the viral copy numbers ranged from 0.05 to 0.18 per PCR reaction, or from 0.001 to 0.006 per cell. For positive controls of HPV detection, eight FFPE samples were obtained from the following patients: four cervical cancers (two patients with HPV16 and two with HPV18 infection) and four oropharyngeal cancers (two patients with HPV16 and two with HPV18 infection). The HPV copy number of these positive control tissues ranged from 0.04 to 491.46 copies per reaction, or from 0.0002 to 1.41 copies per cell (Table 1). Thus, the HPV copy number in HPV-positive GBMs tended to be lower than those observed in the HPV-infected cervical cancers and oropharynx cancers that were used as positive controls.

Cases of GBM may be infected with HPVs other than HPV16 and HPV18 [24]. Therefore, to determine the detection frequency and types of HPV, the GBM samples were also subjected to standard PCR using the primers that were employed for the quantitative PCR assay as well as GP5+/GP6+ primers [25], or to nested PCR using the first primers MY09/11 and the second primers GP5+/GP6+ [25, 26]. The PCR products were sequenced directly, and the sequencing data obtained were BLAST searched using the National Center for Biotechnology Information (NCBI) database. Overall, eight out of 39 (21%) samples were positive for HPV by nested PCR, and all positive cases carried high-risk-type HPV. Six patients were infected with HPV16 and two patients with HPV18.

To explore whether contamination of the normal brain tissues affected the PCR results, we examined normal brain tissues from two GBM cases that harbored the HPV genome (cases 29 and 37). The normal brain tissues were obtained during surgery and stocked as FFPE tissues. As a result, HPV DNA was not detected in the non-neoplastic tissues, suggesting that that the HPV positivity resulted from HPV-infected GBM tumor cells.

To evaluate the expression of HPV antigen, immunohistochemistry was performed using the mouse monoclonal antibody K1H8 against the HPV major capsid protein [27, 28]. This antibody is a broadly-reactive antibody to the following HPV types: 6, 11, 16, 18, 31, 33, 42, 51, 52, 56, and 58. The immunohistochemical study was carried out on three GBM samples, cases 29, 37, and 39, for which enough material was available. These cases were shown to be positive for HPV16 or HPV18 DNA by PCR assays (Table 1). Sample of HPV-positive cervical cancer (HPV16-P2) was used as a positive control. All cases showed positivity for staining of the HPV major capsid protein (Figure 1), indicating that the GBM tumor cells expressed the HPV-derived antigen. The immunochemical signal was detected in the nucleus of tumor cells, partially in the cytoplasm.
Figure 1

Immunohistochemical staining of GBM tumor cells for HPV major capsid protein. Immunohistochemical analysis using the K1H8 monoclonal antibody confirmed the expression of the HPV major capsid protein in the nucleus of tumor cells, partially in the cytoplasm. (A) Case 29; (B) Case 37. Original magnification × 100.

Discussion

The presence of HCMV in GBM was first reported by Cobbs and colleagues [2]. Since this pioneer report, a controversy was generated regarding the presence or absence of this virus in this type of tumor [1113]. Further studies argued that the discrepancy of the results was possibly related to technical reasons, such as differences in the sensitivity of the methods used by different groups, and a consensus was reached that HCMV sequences exist in most, but not all, GBMs [29]. However, this consensus was achieved based on findings from Caucasian patients with GBM, and information on the geographic variability of HCMV prevalence in this type of tumor is scarce. In this study, we measured the HCMV loads in both FFPE and frozen GBM tumors from 39 Japanese patients using highly sensitive quantitative PCR. Our quantitative PCR analysis detected eight copies of HCMV DNA mixed with DNA extracted from 104 HCMV-negative cells. No cases harbored detectable HCMV genomes. Furthermore, nested PCR assays did not detect HCMV in GBM tissues. These results indicate that HCMV is unlikely to play a direct role in the pathogenesis of GBM in cases collected in the south of Japan. Recently, another research group was also unable to demonstrate the presence of HCMV genomes in GBM samples from a population of patients from the central region of Japan [15]. The absence of HCMV in Japanese patients with GBM shown by these two independent studies raises the possibility that the prevalence of HCMV in GBM varies among populations with different ethnic origins. Worldwide epidemiology studies have shown that individuals of European descent are more frequently affected by GBM than are those of Asian or African descent [30, 31]. In the US, the incidence of GBM is two or more times greater in white than in black people [30, 32]. Thus, differences in incidence between Western and Asian countries and among ethnic groups residing in the US suggest a genetic predisposition to GBM. GBM is a tumor that arises from glial cells. If HCMV, which is a ubiquitous herpesvirus that is present in the majority of the population worldwide, is a predominant risk factor for GBM, it is conceivable that the susceptibility of glial cells to HCMV infection might vary according to race. It is known that clinical HCMV isolates display genetic polymorphisms in multiple genes, which are supposed to be related to strain-specific tissue tropism and to the ability to established persistent infection [33]. The most polymorphic genes are those that encode viral envelope glycoproteins, which play important roles in virus entry and in cell-to-cell virus spread [33, 34]. A survey showed that the genotypic variants of the gene that encodes glycoprotein N can be divided into four groups according to the geographical provenance of clinical HCMV isolates, i.e., European, Northern American, Australian, and Chinese types [35]. Thus, genetic polymorphisms in variants isolated from geographically and migrationally different regions might be implicated in different HCMV-related pathogeneses according to race. Therefore, our present findings should prompt further investigation of the prevalence of HCMV in a series of GBM samples from diverse regions of the world, especially in Asia and Africa, as well as studies aimed at determining whether the different detection rates of HCMV are caused by ethnic variation, rather than technical sensitivity.

To date, three polyomaviruses, SV40, JCV, and BKV, have been suggested to be associated with the development of brain tumors [1, 36, 37]. A recent serological study showed a significant association between SV40 and a subset of GBM cases [16]. Because serological cross-reactivity is known among the polyomavirus family [38], it is worthwhile to test the association between new human polyomaviruses and GBM. Furthermore, it has been proposed that polyomaviruses play a synergistic role with other viruses in oncogenic transformation [39]. In this context, it is worth investigating whether HCMV-infected GBM is also coinfected with human polyomaviruses. In this study, we explored for the first time the existence of four newly discovered human polyomaviruses, MCPyV, HPyV6, HPyV7, and HPyV9, in GBMs. However, the polyomavirus DNA sequences were not detectable, suggesting that these polyomaviruses are unlikely to play a pathogenetic role in our patients with GBM.

We also searched for the viral DNAs of two oncogenic herpesviruses, EBV and HHV8, in GBMs, with negative results. Recently, Cimino et al. [14] reported that the EBV DNA sequence was found in five out of 21 (24%) patients from the US with high-grade gliomas using next-generation sequencing analysis. Although the discrepancy in the EBV prevalence rates might be explained in part by geographic epidemiological variations in patients, or merely by differences in the technical approaches used, our study suggests that EBV and HHV8 are not key pathogens in the development of GBM.

HPV is a common oncogenic virus in human. Recently, Vidone et al.[24] reported that HPV DNA was detected in 12 out of 52 Italian patients with GBM (23%) using nested PCR. Among their 12 HPV-positive cases, three cases were infected with HPV16 and nine were infected with HPV6 (low-risk type). In the present study, we found eight HPV-positive GBMs (21%). The detection rate was very similar to that obtained in the Italian population. In contrast, our study showed that the detectable HPVs were all of high-risk types (HPV16 and HPV18). Importantly, we measured for the first time the HPV viral loads in GBM tissues, and found that the copy numbers of infected HPV were relatively low compared with those detected in the HPV-positive cervical cancers and oropharyngeal cancers that were used as positive controls. The HPV genome was not detectable in controlled normal brain tissues. Currently, it is unknown whether persistent HPV infection is directly associated with gliomagenesis in a subset of patients. However, detection of the HPV major capsid protein suggest that production of viral protein from HPV genome is ongoing in GBM tumor cells. Otherwise, HPV might be just a transient ‘hit and run’ infectious pathogen, which would explain the small number of HPV-positive GBMs and lower viral loads detected in the tumor tissues. According to this theory, HCMV may first begin to proliferate in the glial cells and then it may cause cell proliferation. Additional cellular gene mutations during tumor progression may in part render HCMV expression dispensable for gliomagenesis.

Conclusions

This was the first presentation of data regarding the prevalence of various viruses, including HCMV, human oncogenic viruses (EBV, HHV8, HPV, and MCPyV), and new human polyomaviruses (HPyV6, HPyV7, and HPyV9) in GBMs from an Asian population. In contrast with many previous reports based on Caucasian patients, we were not able to obtain direct evidence to support the association between HCMV and GBM. Furthermore, it is unlikely that GBM is associated with human oncogenic viruses, including EBV, HHV8, and MCPyV. However, our investigations demonstrated the presence of the viral genome and protein of high-risk-type HPVs in a subset of patients with GBMs. These findings should stimulate further large-scale worldwide epidemiological and virological studies aimed at defining the pathogenicity of HPV-positive GBM.

Methods

Patients and samples

This study included 39 Japanese patients with GBM grade IV (22 men and 17 women). The median age of the patients was 68 years (range, 4–88 years). Thirty-one FFPE tumor tissues (denoted as cases 1–31) and eight frozen tumor tissues (cases 32–39) were obtained from patients from the Kochi University Hospital. The patients resided in the Kochi prefecture, which is located on Shikoku Island in southern Japan. This study was approved by the Ethics Committee of Kochi Medical School, Kochi University.

DNA extraction and detection of viral DNAs

For DNA extraction from FFPE tumors, three 5-μm-thick slices were prepared for DNA extraction using a ReliaPrep FFPE gDNA Miniprep System (Promega, Tokyo, Japan). From frozen tumor samples or cultured cells, DNA was isolated using a QIAamp DNA Mini Kit (Qiagen, Tokyo, Japan).

Two hundred nanograms of extracted DNA was analyzed for the detection and quantification of eight different viruses (HCMV, MCPyV, HPyV6, HPyV7, HPyV9, EBV, HHV8, and HPV) via TaqMan-based real-time PCR using a StepOne Plus Real-Time PCR System (Life Technologies, Tokyo, Japan). Real-time PCR reactions and quantitative analyses were performed primarily based on methods described previously [21, 22, 4045]. The primers and probes used in this study are shown in Table 2. The reaction mixture used for all real-time PCR assays was prepared as follows: TaqMan Gene Expression Master Mix (Life Technologies), 900 nM of each primer, 250 nM dual-labeled probe, and 200 ng of DNA. The PCR conditions were as follows: 50°C for 2 min and 95°C for 10 min, followed by 50 cycles of 95°C for 15 s and 60°C for 1 min. Collected data were analyzed using StepOne Software v2.2 (Life Technologies). The housekeeping gene RNaseP was used as an internal control, and the PCR mixture without the template DNA was used as a negative control for each experiment.
Table 2

Sequences of the primers and probes used for real-time quantitative PCR analysis

Target

Sequence (5′ → 3′)

Reference

HCMV

gB

F

GGCGAGGACAACGAAATCC

[21]

  

R

TGAGGCTGGGAAGCTGACAT

  

probe

FAM-TTGGGCAACCACCGCACTGAGG-TAMRA

 

IE

F

GACTAGTGTGATGCTGGCCAAG

[22]

  

R

GCTACAATAGCCTCTTCCTCATCTG

  

probe

FAM-AGCCTGAGGTTATCAGTGTAATGAAGCGCC-TAMRA

MCPyV

ST

F

GCAAAAAAACTGTCTGACGTGG

[40]

  

R

CCACCAGTCAAAACTTTCCCA

  

probe

FAM-TATCAGTGCTTTATTCTTTGGTTTGGATTTC-TAMRA

HPyV6

LT

F

TGGTCCCCTTTTGTAACAGC

[41]

  

R

GCCAGAATTGCCAGAGGATA

  

probe

FAM-TGCAAACATGGCTTATGCAGAAA-TAMRA

HPyV7

LT

F

ACTGGTTCCCACCAAATGAG

[41]

  

R

TGCATAAACCAGGCCTTAAAA

  

probe

FAM-CACCCTTTTTGCAAAAGCCTTT-TAMRA

HPyV9

VP1

F

TGCTGTTGATATTGTTGGAATTCA

[42]

  

R

AACAACCCGTTTCCTTAGAGTTACA

  

probe

FAM-CTGGAGAGGCCTACCT-NFQ-MGB

EBV

LMP1

F

GTTGATCTCCTTTGGCTCCTC

[43]

  

R

GTGTCTGCCCTCGTTGG

  

probe

FAM-TTGTTGAGGGTGCGGGAGGGAGTCATCGTGG-TAMRA

HPV16

E6

F

AGGACCCACAGGAGCGAC

[44]

  

R

AGTCATATACCTCACGTCGCAGT

  

probe

FAM-ATGCACAGAGCTGCAAACAA-TAMRA

HPV18

L1

F

GGTTCAGGCTGGATTGCG

[44]

  

R

TACACGCACACGCTTGGC

  

probe

FAM-TCGCAAACGTTCTGCTCC-TAMRA

HHV8

ORF26

F

AGCCGAAAGGATTCCACCAT

[45]

  

R

TCCGTGTTGTCTACGTCCAG

  

probe

FAM-TGCAGCAGCTGTTGGTGTACCACAT-TAMRA

RNase P

 

F

AGATTTGGACCTGCGAGCG

[40]

  

R

GAGCGGCTGTCTCCACAAGT

  

probe

FAM-TTCTGACCTGAAGGCTCTGCGCG-TAMRA

DNA sequencing analysis

After the amplification of DNA by standard PCR or nested PCR, the PCR products were purified with a High Pure PCR Product Purification Kit (Roche Diagnostics, Tokyo, Japan) and then sequenced directly using an ABI Prism BigDye Terminator v1.1 Cycle Sequencing Kit (Life Technologies). The sequenced products were analyzed using a model 3130 Genetic Analyzer (Life Technologies). The nucleotide sequences obtained were aligned and edited with BioEdit software (Ibis Biosciences, Carlsbad, CA, USA).

Immunohistochemistry

To detect HPV protein, immunohistochemistry was performed on FFPE tissue sections using a mouse monoclonal antibody, K1H8 against the HPV major capsid protein [27, 28]. The immunohistochemical study was carried out using a VENTANA DISCOVERY autostainer system according to the protocol provided by the manufacturer (Roche Diagnostics, Tokyo, Japan). The antomated protocol is based on an indirect biotin-avidin system using a biotinylated universal secondary antibody and diaminobenzidine substrate with hematoxylin counterstainig.

Abbreviations

HCMV: 

Human cytomegalovirus

GBM: 

Glioblastoma multiforme

SV40: 

Simian virus 40

JCV: 

JC virus

MCPyV: 

Merkel cell polyomavirus

HPyV6: 

Human polyomavirus 6

HPyV7: 

Human polyomavirus 7

HPyV9: 

Human polyomavirus 9

EBV: 

Epstein–Barr virus

HHV8: 

Human herpesvirus 8

HPV: 

Human papillomavirus

IE: 

Immediate early

gB: 

Glycoprotein B

FFPE: 

Formalin-fixed paraffin-embedded

BKV: 

BK virus.

Declarations

Financial support

This work was partly supported by the JSPS KAKENHI grant numbers 26461423 and 25860829.

Authors’ Affiliations

(1)
Department of Microbiology and Infection, Kochi Medical School, Kochi University
(2)
Division of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University
(3)
Department of Neurosurgery, Kochi Medical School, Kochi University
(4)
Laboratory of Diagnostic Pathology, Kochi Medical School, Kochi University

References

  1. White MK, Pagano JS, Khalili K: Viruses and human cancers: a long road of discovery of molecular paradigms.Clin Microbiol Rev 2014, 27:463–81. 10.1128/CMR.00124-13View ArticlePubMedPubMed CentralGoogle Scholar
  2. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, et al.: Human cytomegalovirus infection and expression in human malignant glioma.Cancer Res 2002, 62:3347–50.PubMedGoogle Scholar
  3. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, et al.: Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma.Neuro Oncol 2008, 10:10–8. 10.1215/15228517-2007-035View ArticlePubMedPubMed CentralGoogle Scholar
  4. Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R: Detection of human cytomegalovirus in different histological types of gliomas.Acta Neuropathol 2008, 116:79–86. 10.1007/s00401-008-0359-1View ArticlePubMedPubMed CentralGoogle Scholar
  5. Lucas KG, Bao L, Bruggeman R, Dunham K, Specht C: The detection of CMV pp 65 and IE1 in glioblastoma multiforme.J Neurooncol 2011, 103:231–8. 10.1007/s11060-010-0383-6View ArticlePubMedGoogle Scholar
  6. dos Santos CJ, Stangherlin LM, Figueiredo EG, Corrêa C, Teixeira MJ, da Silva MC: High prevalence of HCMV and viral load in tumor tissues and peripheral blood of glioblastoma multiforme patients.J Med Virol 2014, 86:1953–61. 10.1002/jmv.23820View ArticlePubMedGoogle Scholar
  7. Rahbar A, Orrego A, Peredo I, Dzabic M, Wolmer-Solberg N, Strååt K, et al.: Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival.J Clin Virol 2013, 57:36–42. 10.1016/j.jcv.2012.12.018View ArticlePubMedGoogle Scholar
  8. Rahbar A, Stragliotto G, Orrego A, Peredo I, Taher C, Willems J, et al.: Low levels of human cytomegalovirus infection in glioblastoma multiforme associates with patient survival: a case-control study.Herpesviridae 2012, 3:3. 10.1186/2042-4280-3-3View ArticlePubMedPubMed CentralGoogle Scholar
  9. Stragliotto G, Rahbar A, Solberg NW, Lilja A, Taher C, Orrego A, et al.: Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study.Int J Cancer 2013, 133:1204–13. 10.1002/ijc.28111View ArticlePubMedGoogle Scholar
  10. Söderberg-Nauclér C, Rahbar A, Stragliotto G: Survival in patients with glioblastoma receiving valganciclovir.N Engl J Med 2013, 369:985–6. 10.1056/NEJMc1302145View ArticlePubMedGoogle Scholar
  11. Lau SK, Chen YY, Chen WG, Diamond DJ, Mamelak AN, Zaia JA, et al.: Lack of association of cytomegalovirus with human brain tumors.Mod Pathol 2005, 18:838–43. 10.1038/modpathol.3800352View ArticlePubMedGoogle Scholar
  12. Sabatier J, Uro-Coste E, Pommepuy I, Labrousse F, Allart S, Trémoulet M, et al.: Detection of human cytomegalovirus genome and gene products in central nervous system tumours.Br J Cancer 2005, 92:747–50. 10.1038/sj.bjc.6602339View ArticlePubMedPubMed CentralGoogle Scholar
  13. Poltermann S, Schlehofer B, Steindorf K, Schnitzler P, Geletneky K, Schlehofer JR: Lack of association of herpesviruses with brain tumors.J Neurovirol 2006, 12:90–9. 10.1080/13550280600654573View ArticlePubMedGoogle Scholar
  14. Cimino PJ, Zhao G, Wang D, Sehn JK, Lewis JS Jr, Duncavage EJ: Detection of viral pathogens in high grade gliomas from unmapped next-generation sequencing data.Exp Mol Pathol 2014, 96:310–5. 10.1016/j.yexmp.2014.03.010View ArticlePubMedGoogle Scholar
  15. Yamashita Y, Ito Y, Isomura H, Takemura N, Okamoto A, Motomura K, et al.: Lack of presence of the human cytomegalovirus in human glioblastoma.Mod Pathol 2014, 27:922–9. 10.1038/modpathol.2013.219View ArticlePubMedGoogle Scholar
  16. Mazzoni E, Gerosa M, Lupidi F, Corallini A, Taronna AP, D’Agostino A, et al.: Significant prevalence of antibodies reacting with simian virus 40 mimotopes in sera from patients affected by glioblastoma multiforme.Neuro Oncol 2014, 16:513–9. 10.1093/neuonc/not217View ArticlePubMedGoogle Scholar
  17. Piña-Oviedo S, De León-Bojorge B, Cuesta-Mejías T, White MK, Ortiz-Hidalgo C, Khalili K, et al.: Glioblastoma multiforme with small cell neuronal-like component: association with human neurotropic JC virus.Acta Neuropathol 2006, 111:388–96. 10.1007/s00401-006-0050-3View ArticlePubMedGoogle Scholar
  18. Feng H, Shuda M, Chang Y, Moore PS: Clonal integration of a polyomavirus in human Merkel cell carcinoma.Science 2008, 319:1096–100. 10.1126/science.1152586View ArticlePubMedPubMed CentralGoogle Scholar
  19. Imajoh M, Hashida Y, Nemoto Y, Oguri H, Maeda N, Furihata M, et al.: Detection of Merkel cell polyomavirus in cervical squamous cell carcinomas and adenocarcinomas from Japanese patients.Virol J 2012, 9:154. 10.1186/1743-422X-9-154View ArticlePubMedPubMed CentralGoogle Scholar
  20. Hashida Y, Imajoh M, Nemoto Y, Kamioka M, Taniguchi A, Taguchi T, et al.: Detection of Merkel cell polyomavirus with a tumour-specific signature in non-small cell lung cancer.Br J Cancer 2013, 108:629–37. 10.1038/bjc.2012.567View ArticlePubMedPubMed CentralGoogle Scholar
  21. Isomura H, Stinski MF: The human cytomegalovirus major immediate-early enhancer determines the efficiency of immediate-early gene transcription and viral replication in permissive cells at low multiplicity of infection.J Virol 2003, 77:3602–14. 10.1128/JVI.77.6.3602-3614.2003View ArticlePubMedPubMed CentralGoogle Scholar
  22. Wada K, Kubota N, Ito Y, Yagasaki H, Kato K, Yoshikawa T, et al.: Simultaneous quantification of Epstein-Barr virus, cytomegalovirus, and human herpesvirus 6 DNA in samples from transplant recipients by multiplex real-time PCR assay.J Clin Microbiol 2007, 45:1426–32. 10.1128/JCM.01515-06View ArticlePubMedPubMed CentralGoogle Scholar
  23. Tafvizi F, Fard ZT: Detection of human cytomegalovirus in patients with colorectal cancer by nested-PCR.Asian Pac J Cancer Prev 2014, 15:1453–7. 10.7314/APJCP.2014.15.3.1453View ArticlePubMedGoogle Scholar
  24. Vidone M, Alessandrini F, Marucci G, Farnedi A, de Biase D, Ricceri F, et al.: Evidence of association of human papillomavirus with prognosis worsening in glioblastoma multiforme.Neuro Oncol 2014, 16:298–302. 10.1093/neuonc/not140View ArticlePubMedGoogle Scholar
  25. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ: The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR.J Gen Virol 1995, 76:1057–62. 10.1099/0022-1317-76-4-1057View ArticlePubMedGoogle Scholar
  26. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlée F, Hildesheim A, et al.: Improved amplification of genital human papillomaviruses.J Clin Microbiol 2000, 38:357–61.PubMedPubMed CentralGoogle Scholar
  27. Iwasaki T, Sata T, Sugase M, Sato Y, Kurata T, Suzuki K, et al.: Detection of capsid antigen of human papillomavirus (HPV) in benign lesions of female genital tract using anti-HPV monoclonal antibody.J Pathol 1992, 168:293–300. 10.1002/path.1711680309View ArticlePubMedGoogle Scholar
  28. Morshed K: Association between human papillomavirus infection and laryngeal squamous cell carcinoma.J Med Virol 2010, 82:1017–23. 10.1002/jmv.21749View ArticlePubMedGoogle Scholar
  29. Dziurzynski K, Chang SM, Heimberger AB, Kalejta RF, McGregor Dallas SR, Smit M, et al.: Consensus on the role of human cytomegalovirus in glioblastoma.Neuro Oncol 2012, 14:246–55. 10.1093/neuonc/nor227View ArticlePubMedPubMed CentralGoogle Scholar
  30. Wöhrer A, Waldhör T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mösenbacher U, et al.: The Austrian brain tumour registry: a cooperative way to establish a population-based brain tumour registry.J Neurooncol 2009, 95:401–11. 10.1007/s11060-009-9938-9View ArticlePubMedGoogle Scholar
  31. Stiller CA, Nectoux J: International incidence of childhood brain and spinal tumours.Int J Epidemiol 1994, 23:458–64. 10.1093/ije/23.3.458View ArticlePubMedGoogle Scholar
  32. Fan KJ, Pezeshkpour GH: Ethnic distribution of primary central nervous system tumors in Washington, DC, 1971 to 1985.J Natl Med Assoc 1992, 84:858–63.PubMedPubMed CentralGoogle Scholar
  33. Pignatelli S, Dal Monte P, Rossini G, Landini MP: Genetic polymorphisms among human cytomegalovirus (HCMV) wild-type strains.Rev Med Virol 2004, 14:383–410. 10.1002/rmv.438View ArticlePubMedGoogle Scholar
  34. Navarro D, Paz P, Tugizov S, Topp K, La Vail J, Pereira L: Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells.Virology 1993, 197:143–58. 10.1006/viro.1993.1575View ArticlePubMedGoogle Scholar
  35. Pignatelli S, Dal Monte P, Rossini G, Chou S, Gojobori T, Hanada K, et al.: Human cytomegalovirus glycoprotein N (gpUL73-gN) genomic variants: identification of a novel subgroup, geographical distribution and evidence of positive selective pressure.J Gen Virol 2003, 84:647–55. 10.1099/vir.0.18704-0View ArticlePubMedGoogle Scholar
  36. Pagano JS, Blaser M, Buendia MA, Damania B, Khalili K, Raab-Traub N, et al.: Infectious agents and cancer: criteria for a causal relation.Semin Cancer Biol 2004, 14:453–71. 10.1016/j.semcancer.2004.06.009View ArticlePubMedGoogle Scholar
  37. Martini F, Corallini A, Balatti V, Sabbioni S, Pancaldi C, Tognon M: Simian virus 40 in humans.Infect Agent Cancer 2007, 2:13. 10.1186/1750-9378-2-13View ArticlePubMedPubMed CentralGoogle Scholar
  38. Moens U, Van Ghelue M, Song X, Ehlers B: Serological cross-reactivity between human polyomaviruses.Rev Med Virol 2013, 23:250–64. 10.1002/rmv.1747View ArticlePubMedGoogle Scholar
  39. Moens U, Van Ghelue M, Ehlers B: Are human polyomaviruses co-factors for cancers induced by other oncoviruses?Rev Med Virol 2014, 24:343–60. 10.1002/rmv.1798View ArticlePubMedGoogle Scholar
  40. Bhatia K, Goedert JJ, Modali R, Preiss L, Ayers LW: Merkel cell carcinoma subgroups by Merkel cell polyomavirus DNA relative abundance and oncogene expression.Int J Cancer 2010, 126:2240–6.PubMedPubMed CentralGoogle Scholar
  41. Duncavage EJ, Pfeifer JD: Human polyomaviruses 6 and 7 are not detectable in Merkel cell polyomavirus-negative Merkel cell carcinoma.J Cutan Pathol 2011, 38:790–6.PubMedGoogle Scholar
  42. Imajoh M, Hashida Y, Taniguchi A, Kamioka M, Daibata M: Novel human polyomaviruses, Merkel cell polyomavirus and human polyomavirus 9, in Japanese chronic lymphocytic leukemia cases.J Hematol Oncol 2012, 5:25. 10.1186/1756-8722-5-25View ArticlePubMedPubMed CentralGoogle Scholar
  43. Sato T, Fujieda M, Tanaka E, Miyamura M, Chikamoto H, Hisano M, et al.: Monitoring of Epstein-Barr virus load and antibody in pediatric renal transplant patients.Pediatr Int 2008, 50:454–8. 10.1111/j.1442-200X.2008.02579.xView ArticlePubMedGoogle Scholar
  44. Yu D, Chen Y, Wu S, Wang B, Tang YW, Li L: Simultaneous detection and differentiation of human papillomavirus genotypes 6, 11, 16 and 18 by AllGlo quadruplex quantitative PCR.PLoS One 2012, 7:e48972. 10.1371/journal.pone.0048972View ArticlePubMedPubMed CentralGoogle Scholar
  45. Hiatt KM, Nelson AM, Lichy JH, Fanburg-Smith JC: Classic Kaposi Sarcoma in the United States over the last two decades: a clinicopathologic and molecular study of 438 non-HIV-related Kaposi Sarcoma patients with comparison to HIV-related Kaposi Sarcoma.Mod Pathol 2008, 21:572–82. 10.1038/modpathol.2008.15View ArticlePubMedGoogle Scholar

Copyright

© Hashida et al.; licensee BioMed Central. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement